(2022) found that 17.3% of endometrial carcinomas exhibit high CLDN9 protein expression, and these patients had markedly worse 5-year disease-specific survival (62.8%) compared to those with low CLDN9 (87.8%) (66). Here, CLDN9 is linked to endometrial carcinoma.